

[My Account](#) [Subscribe Now](#) [Authors](#) [About Us](#) [Podcasts](#)

Editor's Choice

Global, regional, and national burden of respiratory tract cancers and associated risk factors: 2·26 million new cases of tracheal, bronchus, and lung cancer, and 209 000 cases of larynx cancer were recorded in 2019 globally.

[Read this Article](#)

We publish articles of the highest relevance and impact: we are offering complimentary full-text access to a selection of our top-cited, high-impact content through Dec 31, 2021.

[Explore our top-cited content](#)

EDITORIAL

COVID-19, smoking, and cancer: a dangerous liaison

COMMENT

Imatinib in COVID-19: hope and caution

Battling COVID-19-related mortality: from a fight for ventilators to a cry for oxygen

Population science with individual-level data make for better policies

PRINCIPLE: a community-based COVID-19 platform trial

Moving from collective to distributed epidemiological cancer research

Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease

CORRESPONDENCE

Lung transplantation for COVID-19-associated ARDS

Lung transplantation for COVID-19-associated ARDS

Lung transplantation for COVID-19-associated ARDS – Authors' reply

Time to move away from an oxygen-centric model of pulmonary infarction?

Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply

Implications of the second wave of COVID-19 in India

 CORRECTIONS

Correction to *Lancet Respir Med* 2021; published online June 18. [https://doi.org/10.1016/S2213-2600\(21\)00089-8](https://doi.org/10.1016/S2213-2600(21)00089-8)

Correction to *Lancet Respir Med* 2021; published online June 11. [https://doi.org/10.1016/S2213-2600\(21\)00214-9](https://doi.org/10.1016/S2213-2600(21)00214-9)

 SPOTLIGHT

Living with severe asthma since childhood

Elisa Estenssoro: a career devoted to critical care

COVID-19 and the mental health of children with respiratory illness

The breath of life

Stigma: an unmet public health priority in COPD

 ARTICLES

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the *F508del-CFTR* mutation: a multicentre, phase 3, open-label, extension study

Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study

September 1, 2021

BNT162b2 COVID-19 vaccine and correlates of humoral immune response in health-care workers: a single-centre, longitudinal cohort study

Every deep-drawn breath

Doxycycline for community treatment of suspected COVID-19 in people at home in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

September 1, 2021

Icotinib versus chemotherapy as adjuvant treatment for stage II–III A *EGFR* wild-type non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial

Global, regional, and national burden of respiratory tract cancers and associated risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

September 1, 2021

[Open Access](#)

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

POSITION PAPER

Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement

SERIES

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities

August 26, 2021

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

August 27, 2021

Lymphangioliomyomatosis: pathogenesis, clinical features, diagnosis, and management

August 26, 2021

Sedation in critically ill patients: will the vaporiser replace the syringe?

August 26, 2021

Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial

[View the full list of Online First articles](#)

You are receiving this email because you subscribed to TheLancet.com alerting service.

This email has been sent from The Lancet Respiratory Medicine, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084.

[Update mailing preferences](#) to choose which Lancet journals you receive alerts from. [Follow this link to unsubscribe.](#)

[Privacy Policy](#)

Copyright © 2021 Elsevier Limited except certain content provided by third parties. The Lancet is a trade mark of Elsevier Limited.

Subscription ID: 7fee2401-54e6-4917-95b1-08897c324d24 Webuser ID: 30316685 Results Event ID: 9be60aff-0545-45e7-9282-1df4a21e3697